A non-inferiority trial about the efficacy, safety, and effect on QOL of weekly-DPP-4 inhibitor omarigliptin by the comparison with once-daily-DPP-4 inhibitor linagliptin in maintenance hemodialysis patients with type 2 diabetes.

Trial Profile

A non-inferiority trial about the efficacy, safety, and effect on QOL of weekly-DPP-4 inhibitor omarigliptin by the comparison with once-daily-DPP-4 inhibitor linagliptin in maintenance hemodialysis patients with type 2 diabetes.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Omarigliptin (Primary) ; Linagliptin
  • Indications Diabetes mellitus; Diabetic nephropathies
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top